A new, state-of-the-art multi-modal manufacturing campus, designed to accelerate the delivery of next-generation medicines to patients. Project is estimated to create nearly 500 skilled jobs and is designed to grow in scale, capability and workforce for decades to come.

Part of a larger, previously announced $40 billion company investment.

Expansion of a strategic partnership between Resilience and Eli Lilly to increase U.S. manufacturing of innovative medicines treating diabetes and obesity. The partnership is expected to create at least 400 new high-skilled jobs in the Cincinnati region.

Part of a larger, previously announced $23 billion company investment.

Construction of a new state-of-the-art distribution facility to scale the company’s U.S. Vision operations, enhance supply chain resilience, and meet the needs of more than 40 million patients.

Part of a larger, previously announced $55 billion company investment.

Expansion of two existing facilities across Ohio.

In Bedford, the company is investing $51 million to expand its injectable pharmaceutical manufacturing capabilities, IV bag production, and warehousing and distribution operations. The project is expected to create 300 new jobs.

In Columbus, $216 million is being invested to expand oral solid dose and nasal inhalation manufacturing operations, creating 50 new jobs.

These investments are part of a larger, $1 billion company investment announced in June 2025.

Expansion to support increased drug production and integrate innovative advanced technologies at the company's biologics manufacturing facility in Juncos.

Additional investment at the company’s Juncos biologics manufacturing facility. 

Combined with a $650 million investment in September 2025, this additional investment brings the company’s total commitment to this facility to $950 million.

Investment across two of the company’s three sites in Lebanon, Indiana.

The investment will incorporate new process designs and technologies at one of the company's future active pharmaceutical ingredient sites as well as at its first dedicated genetic medicine manufacturing facility.

Part of a larger, previously announced $23 billion company investment.

Finalized plans to build a manufacturing facility focused on active pharmaceutical ingredients(API) for solid dosage tablets, capsules and RNA therapeutics. The 56,200-square-foot site will expand the company’s presence in North Carolina to five facilities.

Plans were initially announced in November 2025.

Part of a larger, previously announced $23 billion company investment.